# Angiodynamics Inc: Form 10-Q for the period ended Nov 30, 2018

- Company: [Angiodynamics Inc](/companies/ango.md) (CIK 1275187)
- Form: 10-Q
- Filed: 2019-01-07
- Accepted by EDGAR: Jan 7, 2019, 16:13 ET
- Period: 2018-11-30
- Accession: 0001275187-19-000009
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1275187/000127518719000009/ango-113018x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1275187/000127518719000009/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-11-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-09-01 to 2018-11-30 | $91.5m | us-gaap:Revenues |
| Revenue | 6 months, 2018-06-01 to 2018-11-30 | $176.8m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2018-09-01 to 2018-11-30 | $42.4m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2018-06-01 to 2018-11-30 | $83.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2018-09-01 to 2018-11-30 | $49.1m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2018-06-01 to 2018-11-30 | $93.6m | us-gaap:GrossProfit |
| Research and development | 3 months, 2018-09-01 to 2018-11-30 | $7.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2018-06-01 to 2018-11-30 | $15.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2018-09-01 to 2018-11-30 | $4.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2018-06-01 to 2018-11-30 | $4.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-09-01 to 2018-11-30 | $1.3m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2018-06-01 to 2018-11-30 | $2.2m | us-gaap:InterestExpense |
| Income tax | 3 months, 2018-09-01 to 2018-11-30 | $591.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2018-06-01 to 2018-11-30 | $583.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-09-01 to 2018-11-30 | $2.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2018-06-01 to 2018-11-30 | $1.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-09-01 to 2018-11-30 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2018-06-01 to 2018-11-30 | $0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-09-01 to 2018-11-30 | $0.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2018-06-01 to 2018-11-30 | $0.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-09-01 to 2018-11-30 | 38,117,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2018-06-01 to 2018-11-30 | 38,131,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 6 months, 2018-06-01 to 2018-11-30 | $1.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2018-11-30 | $42.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-11-30 | $143.0m | us-gaap:AssetsCurrent |
| Total assets | at 2018-11-30 | $784.0m | us-gaap:Assets |
| Current liabilities | at 2018-11-30 | $49.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-11-30 | $234.4m | us-gaap:Liabilities |
| Long-term debt | at 2018-11-30 | $139.3m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2018-11-30 | $5.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2018-11-30 | $549.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 39,682 characters.

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

### Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

### EXECUTIVE OVERVIEW

### Company and Market

We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Most of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or longer-term use.

Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence; changes in the regulatory environment for medical device; and fluctuations in the global economy.

Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions to our product offerings are created through internal product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in research and development activities and business development opportunities and feel confident that our existing capital structure and free cash flow generation will allow us to properly fund those activities. This was evident with the BioSentry and RadiaDyne acquisitions noted below.

On August 14, 2018, the Company acquired the BioSentry Tract Sealant System (BioSentry) technology from Surgical Specialties, LLC, a medical device company headquartered in Westwood, Massachusetts for a total purchase price of $39.8 million of which $37.0 million was paid on August 14, 2018 and $2.8 million was recorded as contingent consideration. The contingent consideration liability was recorded at fair value and will be payable to SSC upon fulfillment of certain hydrogel orders. This is part of the Company’s strategic focus on building a continuum of care within the oncology space. Refer to Note 2 for further disclosure on the acquisition.

On September 21, 2018, the Company acquired RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes. The aggregate purchase price of $75.0 million included an upfront payment of $47.9 million, contingent consideration with an estimated fair value of $22.3 million, an indemnification holdback of $4.6 million and a purchase price holdback of $0.2 million. The fair value of $22.3 million is comprised of $16.5 million for the revenue milestones and $5.8 million for the technical milestones. The $4.6 million indemnification holdback is recorded in other long-term liabilities and the $0.2 million purchase price holdback is recorded in accrued liabilities. This acquisition expands the Company’s growing Oncology business by adding RadiaDyne’s early-stage, proprietary OARtrac® real-time radiation dose monitoring platform and other market-leading oncology solutions, including the IsoLoc®/ImmobiLoc® and Alatus® balloon stabilizing technologies.

We sell our products in the United States primarily through a direct sales force, and outside the U.S. through a combination of a direct sales and distributor relationships. We expect our businesses to grow in both sales and profitability through geographic expansion, market penetration, new product introductions and increasing our direct presence internationally.

In evaluating the operating performance of our business, management focuses on revenue, gross margin, operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the three and six months ended November 30, 2018 compared to the three and six months ended November 30, 2017 follows:

Three months ended November 30, 2018:

- Revenue increased by 5.5% to $91.5 million
- Gross margin increased 440 bps to 53.7%
- Operating income increased by $2.9 million to $4.0 million
- Earnings per share increased by $0.05 to $0.06

Six months ended November 30, 2018:

- Revenue increased by 2.7% to $176.8 million
- Gross margin increased 410 bps to 52.9%
- Operating income increased by $3.0 to $4.3 million
- Earnings per share increased by $0.03 to $0.04
- Cash flow provided by operations decreased by $9.1 million to $4.1 million

### New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note 17 to our consolidated financial statements in this Quarterly Report on Form 10-Q.

### Results of Operations for the Three Months ended November 30, 2018 and 2017

For the three months ended November 30, 2018, we reported net income of $2.1 million, or $0.06 per diluted share, on net sales of $91.5 million, compared with net income of $0.2 million, or $0.01 per share, on net sales of $86.7 million during the same quarter of the prior year.

### Net Sales

Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns.

Net sales for the three months ended November 30, 2018 and 2017:

*(in thousands)*

| Net Sales by Global Business Unit | Three months ended Nov 30, 2018 | Nov 30, 2017 | % Growth |
| --- | ---: | ---: | ---: |
| Vascular Interventions & Therapies | $52,494 | $51,368 | 2.2% |
| Vascular Access | 23,723 | 22,574 | 5.1% |
| Oncology | 15,286 | 12,764 | 19.8% |
| Total | $91,503 | $86,706 | 5.5% |
| Net Sales by Geography |  |  |  |
| United States | $71,883 | $68,301 | 5.2% |
| International | 19,620 | 18,405 | 6.6% |
| Total | $91,503 | $86,706 | 5.5% |

For the three months ended November 30, 2018, net sales increased $4.8 million to $91.5 million compared to the same period in the prior year.

#### Vascular Interventions & Therapies

- Total Vascular Interventions & Therapies sales increased $1.1 million primarily attributable to strong performance in Fluid Management and AngioVac. The increase in Fluid Management was attributed to continued efforts around new custom kits. The Company continues to see strong case volumes in AngioVac. AngioVac case volume increased 10% from the prior year due to increased adoption of the Company's unique technology. These increases were partially offset by decreased sales volume of Venous products due to reimbursement challenges.
- U.S. Vascular Interventions & Therapies sales increased $0.6 million due to an increase in volume in Fluid Management and AngioVac. This was partially offset by decreased sales volume of Venous products.
- International Vascular Interventions & Therapies sales increased $0.5 million due to an increase in volume in Angiographic catheters.

#### Vascular Access

- Total Vascular Access sales increased $1.1 million due to growth primarily in our BioFlo businesses. Our BioFlo product lines increased $0.7 million year over year. The Company's BioFlo portfolio now comprises 50% of overall Vascular Access sales, compared to 49% a year ago.
- U.S. Vascular Access sales increased by $0.2 million due to growth in Midlines and BioFlo Dialysis products which continue to gain traction in the marketplace. In addition, there was $0.2 million of sales of the BIIM ultrasound product which was launched in FY19. This was partially offset by competitive pressures in the PICC product lines.
- International Vascular Access sales increased by $0.9 million as the Company continues to expand its global reach of its Vascular Access product offerings.

#### Oncology

- Total Oncology sales increased $2.5 million year over year primarily due to increased sales of NanoKnife capital and disposables along with $1.6 million in sales related to BioSentry products and $1.3 million in sales related to RadiaDyne products. This was partially offset by decreased sales in Radiofrequency Ablation and Microwave disposables. Microwave sales were negatively impacted by the timing of the Company's prior year replacement shipments of $0.9 million which took place in the second quarter of the prior year as a result of the market withdrawal of Acculis.
- U.S. Oncology sales increased by $3.0 million, driven by BioSentry sales of $1.6 million and RadiaDyne sales of $1.3 million.
- International Oncology sales decreased by $0.5 million year over year as a result of decreased RadioFrequency Ablation and Microwave sales which were partially offset by increased NanoKnife disposable sales.

### Gross Profit, Operating expenses, and Other income (expense)

*(in thousands)*

|  | Three months ended Nov 30, 2018 | Nov 30, 2017 | % Change |
| --- | ---: | ---: | ---: |
| Gross profit | $49,109 | $42,731 | 15% |
| Gross profit % of sales | 53.7% | 49.3% |  |
| Research and development | $7,363 | $6,107 | 21% |
| % of sales | 8.0% | 7.0% |  |
| Selling and marketing | $20,269 | $18,967 | 7% |
| % of sales | 22.2% | 21.9% |  |
| General and administrative | $9,336 | $7,540 | 24% |
| % of sales | 10.2% | 8.7% |  |

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit increased by $6.4 million compared to the prior year. The increase is primarily attributable to the following:

- Sales volume and mix contributed $2.0 million of favorability offset by increased freight expense of $0.3 million.
- Sales of BioSentry and RadiaDyne products contributed $2.0 million to gross profit.
- $1.0 million of favorability as a result of the plant consolidation.
- Prior year reserve of $1.7 million related to the discontinuation of our RadioFrequency Ablation product in Japan.
- The expiration of a royalty agreement in fiscal year 2018 resulted in $0.2 million of favorability compared to the prior year.
- Currency fluctuations had an unfavorable impact of $0.2 million.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense increased $1.3 million compared to the prior year. The increase is primarily attributable to the following:

- $1.2 million increase in new product development and clinical efforts related to the Company’s investment areas of NanoKnife, Thrombus Management and BioFlo.
- $0.2 million increase in backfilling of open positions from prior year.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense increased $1.3 million compared to the prior year. The increase is primarily attributable to the following:

- Compensation and benefits increase of approximately $0.4 million. $0.9 million of the increase is attributed to increased headcount as a result of the BioSentry and RadiaDyne acquisitions offset by lower variable compensation and decreased severance expense.
- Increased travel of $0.3 million as a result of the increased headcount.
- Increased consulting spend of $0.2 million and increased spend related to marketing efforts for new product introductions of $0.4 million.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense increased $1.8 million compared to the prior year. The increase is primarily attributable to the following:

- Compensation and benefits increase of approximately $1.0 million primarily as a result of increased variable compensation, inflation of salaries and benefits, backfilling of prior year openings, increased headcount from the RadiaDyne acquisition and stock based compensation.
- Increased legal and professional fees relating to ongoing litigation that is within the normal course of business of $0.3 million.
- Increased other expenses including supplies of $0.3 million.

*(in thousands)*

|  | Three months ended Nov 30, 2018 | Nov 30, 2017 | $ Change |
| --- | ---: | ---: | ---: |
| Amortization of intangibles | $5,188 | $4,146 | $1,042 |
| Change in fair value of contingent consideration | $244 | $82 | $162 |
| Acquisition, restructuring and other items, net | $2,728 | $4,766 | $(2,038) |
| Other expense | $(1,250) | $(1,040) | $(210) |

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

- The increase in amortization expense from the prior year is due to intangible asset additions as a result of the BioSentry and RadiaDyne acquisitions. The BioSentry acquisition increased intangible assets by $25.6 million and resulted in additional amortization expense of $0.6 million. The RadiaDyne acquisition increased intangible assets by $22.1 million and resulted in additional amortization expense of $0.4 million.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

- The increase from the prior year is due to the contingent considerations that were recorded as part of the BioSentry and RadiaDyne acquisitions of $2.8 million and $22.3 million, respectively. The change in the fair value in contingent consideration is the result of amortization of the present value discount of $0.2 million. In addition, in the second quarter of fiscal year 2018, the final minimum payment was made on the AngioVac product contingent consideration and a $2.1 million payment was made on the Microsulis contingent consideration during the first quarter of fiscal 2019. Only one minimum payment is remaining on the Microsulis contingent consideration.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net decreased by $2.0 million compared to the prior year. The decrease is primarily attributable to the following:

- M&A expenses of $1.5 million were incurred in the second quarter of fiscal year 2019 compared to $1.0 million in the prior year.
- Legal expenses, related to litigation that is outside of the normal course of business, of $0.9 million were recorded in the second quarter of fiscal year 2019 compared to $2.2 million in the prior year.
- In the second quarter of fiscal year 2018, the Company incurred $1.4 million of expense which consisted of $0.6 million of severance and $0.8 million of costs to move the product lines related to the plant consolidation that was announced in the third quarter of fiscal year 2017. The plant consolidation was completed in the fourth quarter of fiscal year 2018; therefore, only $0.1 million of expense was incurred in the second quarter of fiscal year 2019.

Other expenses - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

- The increase in other expenses from the prior year of $0.2 million is due to increased interest expense of $0.6 million primarily due to the $55.0 million draw on the revolver during the second quarter. In addition, other expenses also increased by $0.3 million. These increases were partially offset by foreign currency fluctuations of $0.6 million.

### Income Tax Provision (Benefit)

*(in thousands)*

|  | Three months ended Nov 30, 2018 | Nov 30, 2017 |
| --- | ---: | ---: |
| Income tax expense (benefit) | $0.6 | $(0.2) |
| Effective tax rate including discrete items | 21.6% | (200.0)% |

Our effective tax rate including discrete items for the three month periods ended November 30, 2018 and 2017 was 21.6% and negative (200.0)%, respectively. In fiscal 2019, the Company's effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes and state taxes.

The estimated annual effective tax rate, however, prior to discrete items was 26.3% in the second quarter of fiscal 2019, as compared to 59.8% for the same period in fiscal 2018.

The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal 2016, except the naked credit deferred tax liability.

Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of November 30, 2018. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.

### Results of Operations for the Six Months ended November 30, 2018 and 2017

For the six months ended November 30, 2018, we reported net income of $1.7 million, or $0.04 per diluted share, on net sales of $176.8 million, compared with net income of $0.2 million, or $0.01 per share, on net sales of $172.1 million during the same quarter of the prior year.

### Net Sales

Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns.

Net sales for the six months ended November 30, 2018 and 2017:

*(in thousands)*

| Net Sales by Global Business Unit | Six Months Ended Nov 30, 2018 | Nov 30, 2017 | % Growth |
| --- | ---: | ---: | ---: |
| Vascular Interventions & Therapies | $102,488 | $101,234 | 1.2% |
| Vascular Access | 47,513 | $45,812 | 3.7% |
| Oncology | 26,842 | $25,071 | 7.1% |
| Total | $176,843 | $172,117 | 2.7% |
| Net Sales by Geography |  |  |  |
| United States | $139,567 | $137,232 | 1.7% |
| International | 37,276 | $34,885 | 6.9% |
| Total | $176,843 | $172,117 | 2.7% |

For the six months ended November 30, 2018, net sales increased $4.7 million to $176.8 million compared to the same period in the prior year.

#### Vascular Interventions & Therapies

- Total Vascular Interventions & Therapies sales increased $1.3 million primarily attributable to strong performance in Fluid Management, Angiographic catheters and AngioVac. The increase in Fluid Management was attributed to continued efforts around new custom kits. The Company continues to see strong results in the Angiographic catheters business and has maintained the majority of the business from a competitor's recall. The Company continues to see strong case volumes in AngioVac. AngioVac case volume increased 12% percent from the prior year due to increased adoption of the Company's unique technology. These increases were partially offset by decreased sales volume of Venous products due to reimbursement challenges.
- U.S. Vascular Interventions & Therapies sales increased $0.8 million due to an increase in volume in Fluid Management, Angiographic catheters and AngioVac. This was partially offset by decreased sales volume of Venous products.
- International Vascular Interventions & Therapies sales increased $0.5 million due to an increase in volume in Venous and Angiographic catheters.

#### Vascular Access

- Total Vascular Access sales increased $1.7 million due to growth primarily in our BioFlo businesses. Our BioFlo product lines increased $1.3 million year over year. The Company's BioFlo portfolio now comprises 50% of overall Vascular Access sales, compared to 49% a year ago.
- U.S. Vascular Access sales increased by $0.1 million due to growth in Midlines and BioFlo Dialysis products which continue to gain traction in the marketplace. This was partially offset by competitive pressures in the PICC product line.
- International Vascular Access sales increased by $1.6 million as the Company continues to expand its global reach of its Vascular Access product offerings.

#### Oncology

- Total Oncology sales increased $1.8 million year over year primarily due to increased sales of NanoKnife capital and disposables of $1.2 million along with $1.9 million in sales from BioSentry products and $1.3 million in sales from RadiaDyne products. This was partially offset by decreased sales in Radiofrequency Ablation and Microwave disposables. Microwave sales were negatively impacted by the timing of the Company's prior year replacement shipments of $2.5 million which took place in the first and second quarters of the prior year as a result of the market withdrawal of Acculis.
- U.S. Oncology sales increased by $2.0 million primarily due to increased sales of NanoKnife capital and disposables along with $1.9 million in sales related to BioSentry products and $1.3 million in sales related to RadiaDyne products. This was partially offset by a $0.7 million decrease in sales of RadioFrequency Ablation and Microwave capital and disposables.
- International Oncology sales decreased by $0.2 million due to decreased RadioFrequency Ablation and Microwave sales of $1.4 million, partially offset by increased NanoKnife capital and disposable sales of $1.2 million.

### Gross Profit, Operating expenses, and Other income (expense)

*(in thousands)*

|  | Six months ended Nov 30, 2018 | Nov 30, 2017 | % Change |
| --- | ---: | ---: | ---: |
| Gross profit | $93,576 | $83,960 | 11% |
| Gross profit % of sales | 52.9% | 48.8% |  |
| Research and development | $15,025 | $12,548 | 20% |
| % of sales | 8.5% | 7.3% |  |
| Selling and marketing | $39,702 | $38,369 | 3% |
| % of sales | 22.5% | 22.3% |  |
| General and administrative | $17,832 | $15,596 | 14% |
| % of sales | 10.1% | 9.1% |  |

33

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit increased by $9.6 million compared to the prior year. The increase is primarily attributable to the following:

- Sales volume/mix contributed $2.6 million of favorability year over year offset by increased freight expense of $0.6 million.
- Sales of BioSentry and RadiaDyne products contributed $2.3 million to gross profit.
- $2.0 million of favorability as a result of the plant consolidation.
- Prior year reserve of $1.7 million related to the discontinuation of our RadioFrequency Ablation product in Japan.
- The expiration of a royalty agreement in fiscal year 2018 resulted in $1.5 million of favorability compared to the prior year.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense increased $2.5 million compared to the prior year. The increase is primarily attributable to the following:

- $1.8 million increase in new product development and clinical efforts related to the Company’s investment areas of NanoKnife, Thrombus Management and BioFlo.
- $0.6 million increase in backfilling of open positions from prior year.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense increased $1.3 million compared to the prior year. The increase is primarily attributable to the following:

- Compensation and benefits increase of approximately $0.5 million. $0.8 million of the increase is attributed to increased headcount as a result of the BioSentry and RadiaDyne acquisitions offset by lower variable compensation and decreased severance expense.
- Increased travel of $0.5 million as a result of the increased headcount.
- Increased consulting spend of $0.2 million and increased spend for trade shows and meeting expenses of $0.4 million were partially offset by $0.2 million decrease in office supplies and $0.1 million in lease expense.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense increased $2.2 million compared to the prior year. The increase is primarily attributable to the following:

- Compensation and benefits increase of approximately $1.8 million primarily as a result of increased variable compensation, inflation of salaries and benefits, backfilling of prior year openings, increased headcount from the RadiaDyne acquisition and stock based compensation.
- Increased other expenses including supplies of $0.2 million and lease expense of $0.1 million.

*(in thousands)*

|  | Six months ended Nov 30, 2018 | Nov 30, 2017 | $ Change |
| --- | ---: | ---: | ---: |
| Amortization of intangibles | $9,304 | $8,242 | $1,062 |
| Change in fair value of contingent consideration | $256 | $187 | $69 |
| Acquisition, restructuring and other items, net | $7,150 | $7,755 | $(605) |
| Other expense | $(2,053) | $(1,196) | $(857) |

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

- The increase in amortization expense from the prior year is due to intangible asset additions as a result of the BioSentry and RadiaDyne acquisitions. The BioSentry acquisition increased intangible assets by $25.6 million and resulted in additional amortization expense of $0.6 million. The RadiaDyne acquisition increased intangible assets by $22.1 million and resulted in additional amortization expense of $0.4 million.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

- The increase from the prior year is due to the contingent considerations that were recorded as part of the BioSentry and RadiaDyne acquisitions of $2.8 million and $22.3 million, respectively. The change in the fair value in contingent consideration is the result of amortization of the present value discount of $0.3 million. In addition, in the second quarter of fiscal year 2018, the final minimum payment was made on the AngioVac product contingent consideration and a $2.1 million payment was made on the Microsulis contingent consideration during the first quarter of fiscal 2019. Only one minimum payment is remaining on the Microsulis contingent consideration.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net decreased by $0.6 million compared to the prior year. The decrease is primarily attributable to the following:

- M&A expenses of $2.9 million were incurred in fiscal year 2019 compared to $1.1 million in the prior year.
- Legal expenses, related to litigation that is outside of the normal course of business, of $3.7 million was recorded in fiscal year 2019 compared to $3.8 million in fiscal year 2018.
- For the six months ended 2018, the Company incurred $2.6 million of expense which consisted of $1.1 million of severance and $1.4 million of costs to move the product lines related to the plant consolidation that was announced in the third quarter of fiscal year 2017. The plant consolidation was completed in the fourth quarter of fiscal year 2018; therefore, only $0.3 million of expense was incurred for the six months ended 2019.

Other expenses - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

- The increase in other expenses from the prior year of $0.9 million is due to increased interest expense of $0.7 million primarily due to the $55.0 million draw on the revolver during the second quarter. In addition, other expenses also increased by $0.5 million. These increases were partially offset by foreign currency fluctuations of $0.1 million.

### Income Tax Provision (Benefit)

*(in thousands)*

|  | Six months ended Nov 30, 2018 | Nov 30, 2017 |
| --- | ---: | ---: |
| Income tax expense (benefit) | $0.6 | $(0.1) |
| Effective tax rate including discrete items | 25.9% | (219.4)% |

Our effective tax rate including discrete items for the three month periods ended November 30, 2018 and 2017 was 25.9% and negative (219.4)%, respectively. In fiscal 2019, the Company's effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes and state taxes.

The estimated annual effective tax rate, however, prior to discrete items was 26.3% in the second quarter of fiscal 2019, as compared to 59.8% for the same period in fiscal 2018.

The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal 2016, except the naked credit deferred tax liability.

Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of November 30, 2018. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.

### Liquidity and Capital Resources

Our cash and cash equivalents totaled $42.8 million as of November 30, 2018, compared with $74.1 million as of May 31, 2018. Marketable securities totaled $1.4 million as of November 30, 2018 and $1.3 million as of May 31, 2018, and consist of an auction rate security. As of November 30, 2018, total principal debt outstanding was $145.0 million and the fair value of contingent consideration payments was $26.5 million.

The table below summarizes our cash flows for the six months ended November 30, 2018 and 2017:

*(in thousands)*

| Cash provided by (used in): | Six Months Ended Nov 30, 2018 | Nov 30, 2017 |
| --- | ---: | ---: |
| Operating activities | $4,086 | $13,201 |
| Investing activities | (86,336) | (1,222) |
| Financing activities | 51,254 | (10,262) |
| Effect of exchange rate changes on cash and cash equivalents | (280) | 595 |
| Net change in cash and cash equivalents | $(31,276) | $2,312 |

During the six months ended November 30, 2018 and 2017, cash flows consisted of the following:

#### Cash provided by operating activities

Six months ended November 30, 2018:

- Net income was driven by increased sales and increased gross profit. This was partially offset by higher operating expenses in research and development, selling and marketing and general administrative as well as costs related to our acquisition and restructuring activities.
- The Company continues to focus on optimizing its cash conversion cycle. In the second quarter of fiscal year 2019, working capital was negatively impacted by increased inventory on hand of $1.0 million. Additionally, even though days sales outstanding ("DSO") decreased by two days, receivables negatively impacted working capital by $3.1 million as a result of increased sales in the quarter. Also, the $12.5 million DOJ settlement payment that was made during the first quarter of fiscal year 2019 negatively impacted working capital from accounts payable and accrued liabilities.

Six months ended November 30, 2017:

- Net income was driven by higher sales and higher gross margins.
- With regards to working capital, the Company focused on optimizing DSO which contributed to $2.3 million of working capital improvement. This working capital improvement was offset by a $4.5 million decrease in accounts payable and accrued liabilities.

#### Cash used in investing activities

Six months ended November 30, 2018 and 2017:

- $1.4 million in fixed asset additions, primarily for maintenance of equipment versus $1.2 million in the prior year.
- $37.0 million cash payment to acquire the BioSentry product from SSC and a $47.9 million cash payment to acquire RadiaDyne as described in Note 2 to the financial statements.

#### Cash used in financing activities

Six months ended November 30, 2018 and 2017:

- $55.0 million draw on the revolver as a result of the RadiaDyne acquisition described in Note 2 to the financial statements.
- $2.5 million in repayments on long-term debt in both the current year and prior year. This is consistent with the required amortization payment on the Term Loan.
- $0.9 million of proceeds from stock option and ESPP activity versus $1.7 million in the prior year.
- $2.1 million payment on earn-out liabilities in the current year compared to $9.5 million in the prior year as the Company made the final minimum payment on the AngioVac product contingent consideration.

On November 7, 2016, the Company entered into a Credit Agreement that provides for a $100.0 million senior secured term loan facility and a $150.0 million senior secured revolving credit facility, which includes up to a $20.0 million sublimit for letters of credit and a $5.0 million sublimit for swingline loans.

We believe that our current cash and investment balances, together with future cash generated from operations and our revolving credit facility capacity of up to $150.0 million as of November 30, 2018, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. As part of the RadiaDyne acquisition that closed on September 21, 2018, the Company drew $55.0 million on the revolving credit facility. Based on our current leverage ratio of net debt to EBITDA, as defined by the Credit Agreement, the Company could draw approximately $85.0 million more on the remaining $95.0 million of the revolving credit facility. If we seek to make significant acquisitions of other businesses or technologies in the future, we may require additional external financing.

## Market risk

As filed, 2,984 characters.

### Foreign Currency Exchange Rate Risk

We are exposed to market risk from changes in currency exchange rates, as well as interest rate fluctuations on our credit facility and investments that could impact our results of operations and financial position.

We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British pound and Canadian dollar. Approximately 8% of our sales in the second quarter of fiscal 2019 were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations. When the U.S. Dollar strengthens, our sales and gross profit will be negatively impacted. In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other (Expenses) Income. Significant non-functional balances include accounts receivable due from a sub-section of our international customers.

### Interest Rate Risk

On November 7, 2016, we entered into the Credit Agreement which provides for a $100 million senior secured Term Loan and a $150 million Revolving Facility. Interest on both the Term Loan and Revolving Facility is based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.50% to 2.25% respectively. In the event of default, the interest rate may be increased by 2.0%. A 50 basis point (0.50%) increase or decrease in the interest rate would result approximately in a $2.0 million increase or decrease in interest expense over the life of the agreement.

### Concentration of Credit Risk

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, our credit facility and trade accounts receivable.

The Company maintains cash and cash equivalents at various institutions and performs periodic evaluations of the relative credit standings of these financial institutions to ensure their credit worthiness. In addition, the Credit Agreement is structured across five above investment grade banks. The Company has the ability to draw equally amongst the five banks which limits the concentration of credit risk of one institution.

Concentration of credit risk with respect to trade accounts receivable is limited due to the large number of customers that purchase products from the Company. No single customer represents more than 10% of total sales. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Although the Company does not currently foresee a significant credit risk associated with the outstanding accounts receivable, repayment is dependent upon the financial stability of our customers.

## Controls and procedures

As filed, 1,362 characters.

### Evaluation of disclosure controls and procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting for the fiscal quarter ended November 30, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 684 characters.

In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2018 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.

Filed Jan 7, 2019.
Source: SEC EDGAR, the filing index for accession 0001275187-19-000009. Last ingested by Listed: Nov 4, 2026, 20:24 ET. No prices; not investment advice.
